Whether through these or additional mechanisms, it remains evident from our experiments that myeloid MyD88 signaling restricts production of type I interferon in response to RT, thereby limiting adaptive immune control of tumors in pancreatic cancer. Here, MYD88 is linked to pancreatic neoplasm.